CN111024952A - Composite immunomagnetic bead purification kit for ractopamine and salbutamol - Google Patents
Composite immunomagnetic bead purification kit for ractopamine and salbutamol Download PDFInfo
- Publication number
- CN111024952A CN111024952A CN202010030570.0A CN202010030570A CN111024952A CN 111024952 A CN111024952 A CN 111024952A CN 202010030570 A CN202010030570 A CN 202010030570A CN 111024952 A CN111024952 A CN 111024952A
- Authority
- CN
- China
- Prior art keywords
- salbutamol
- ractopamine
- kit
- immunomagnetic
- immunomagnetic beads
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011324 bead Substances 0.000 title claims abstract description 75
- 229940074095 ractopamine Drugs 0.000 title claims abstract description 64
- 229960002052 salbutamol Drugs 0.000 title claims abstract description 64
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title claims abstract description 49
- YJQZYXCXBBCEAQ-UHFFFAOYSA-N ractopamine Chemical compound C=1C=C(O)C=CC=1C(O)CNC(C)CCC1=CC=C(O)C=C1 YJQZYXCXBBCEAQ-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 238000000746 purification Methods 0.000 title claims abstract description 22
- 239000002131 composite material Substances 0.000 title claims abstract description 20
- 239000007790 solid phase Substances 0.000 claims abstract description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims abstract description 9
- 238000002965 ELISA Methods 0.000 claims abstract description 7
- 239000000523 sample Substances 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000007853 buffer solution Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000007885 magnetic separation Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000003761 preservation solution Substances 0.000 claims description 2
- 239000012488 sample solution Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 8
- 238000000926 separation method Methods 0.000 abstract description 5
- 235000013622 meat product Nutrition 0.000 abstract 1
- 230000004913 activation Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
Abstract
The invention provides a composite immunomagnetic bead purification kit of ractopamine and salbutamol, which comprises an immunomagnetic bead solid-phase carrier coupled with an anti-ractopamine antibody and an anti-salbutamol antibody and a matched test kit loaded with the immunomagnetic bead solid-phase carrier. The composite immunomagnetic bead purification kit is characterized in that an immunomagnetic bead solid phase carrier coupled with a ractopamine antibody and a salbutamol antibody is placed into a specific kit, the kit is matched with an immunomagnetic bead purification instrument, enrichment and separation of ractopamine and salbutamol in products such as animal tissues, aquatic products and meat products can be completed automatically, the separation capability is strong, and then the kit is used together with a high performance liquid chromatography method, an enzyme linked immunosorbent assay method and the like, so that the content of ractopamine and salbutamol in a sample can be detected efficiently and accurately.
Description
Technical Field
The invention belongs to the field of sample pretreatment, and particularly relates to a composite immunomagnetic bead purification kit for ractopamine and salbutamol.
Background
In recent years, ractopamine and salbutamol are used as feed additives and are more serious in illegal use in animal husbandry, especially have high residue in internal organs such as the liver of a pig, and the like, and the internal organs are directly harmful to human health after eating.
The existing methods for detecting ractopamine and salbutamol are immunological methods and chromatographic analysis methods. Although the two methods have high sensitivity, sample pretreatment and determination operations are complicated, the cost is high, and the methods are not suitable for screening a large number of samples, so that the establishment of a sample pretreatment method for ractopamine and salbutamol, which is efficient, rapid, simple and high in enrichment and purification effects, has a very important significance in order to rapidly perform quantitative analysis on the content of ractopamine and salbutamol in the samples.
Disclosure of Invention
The invention aims to provide a composite immunomagnetic bead purification kit for ractopamine and salbutamol, aiming at the defects in the prior art, and the kit is used for enriching and purifying the ractopamine and salbutamol in a sample so as to solve the technical problems of complex purification and separation operation, low separation efficiency and the like of ractopamine and salbutamol sample samples.
In order to achieve the purpose, the invention adopts the following technical scheme: a composite immunomagnetic bead purification kit of ractopamine and salbutamol comprises an immunomagnetic bead solid phase carrier coupled with ractopamine antibodies and salbutamol antibodies and a matched test kit for loading the immunomagnetic bead solid phase carrier, wherein the immunomagnetic bead solid phase carrier coupled with the ractopamine antibodies and the salbutamol antibodies is placed into a specific kit, the immunomagnetic beads are used as the solid phase carrier, the surface of the beads is provided with affinity ligands through chemical reaction activation, and the activated beads are coupled with the ractopamine antibodies and the salbutamol antibodies to prepare a sample pretreatment kit capable of realizing rapid enrichment and purification of ractopamine and salbutamol for subsequent measurement by HPLC or enzyme-linked immunosorbent assay.
Preferably, the concentration of the immunomagnetic beads is 5-100 mg/mL.
Preferably, each immunomagnetic bead purification kit contains 0.5-5mg/mL of anti-ractopamine monoclonal antibody and 0.8-8mg/mL of anti-salbutamol monoclonal antibody.
Preferably, the preservation solution of the immunomagnetic beads is PBS buffer solution with pH7.4 and 0.02mo 1/L.
Preferably, the kit specifically comprises the following steps: taking the immunomagnetic beads coupled with the ractopamine antibody and the salbutamol antibody out of the refrigerator, recovering to room temperature, rotating and uniformly mixing, putting the pretreated sample solution into a test tube, transferring the immunomagnetic beads into the test tube, fully rotating and resuspending, rotating and capturing for 20min at room temperature to capture the ractopamine and the salbutamol in the sample to the maximum extent, performing magnetic separation by using a magnetic frame, and slowly discarding the supernatant; washing the captured immunomagnetic beads of the sample by using a cleaning solution for several times, and gently shaking for resuspension and magnetic separation; the sample enrichment and purification solution of ractopamine and salbutamol is realized; and (3) eluting the obtained sample enrichment and purification solution by using an organic solvent as an eluent, shaking for a few seconds at room temperature, carrying out magnetic separation, and obtaining a supernatant which is a sample of ractopamine and salbutamol to be detected, wherein the supernatant can be used for subsequent HPLC or enzyme-linked immunosorbent assay determination.
A composite immunomagnetic bead purification kit of ractopamine and salbutamol is specifically prepared by the following steps:
(1) antibody pretreatment: putting the purified anti-ractopamine monoclonal antibody and the anti-salbutamol monoclonal antibody into a buffer solution with the pH value of 6.550mmol/L for dialysis overnight for 12 hours;
(2) and (3) activation: taking a certain amount of magnetic beads in a reaction tube, carrying out ultrasonic dispersion, heavy suspension and uniform mixing, respectively adding prepared EDC and NHS, placing in a blood mixing machine at room temperature for activation reaction for 2h, and keeping the solution in a suspended and uniformly mixed state all the time;
(3) coupling: magnetic separation is carried out by a magnetic frame, supernatant is slowly poured out, washed three times by PBS buffer solution, and resuspended on a mixing instrument. Adding the pretreated anti-ractopamine monoclonal antibody and the anti-salbutamol antibody into the activated immunomagnetic beads, reacting overnight at room temperature, and placing on a mixing instrument to rotate to keep a suspension state;
(4) and (3) sealing: performing magnetic separation with a magnetic frame, pouring out supernatant, adding 40 μ L ethanolamine solution and BSA blocking solution, blocking at 37 deg.C for 2 hr, and keeping in suspension state;
(5) and (3) storage: washing the immunomagnetic beads with PBS for 3 times, performing magnetic separation, discarding the supernatant, and storing in the immunomagnetic bead storage solution at 4 deg.C.
Compared with the prior art, the invention has the beneficial effects that:
1. the method can quickly and selectively separate and enrich and purify the ractopamine and the salbutamol in the sample in a short time, avoids using a large amount of organic solvents, effectively reduces the interference of background substances, and improves the accuracy and precision of detection;
2. the immunomagnetic bead separation technology is applied, the purification step is not needed after extraction, and the operation is simple, convenient and feasible. The operation does not need large-scale instruments and specially trained professionals, samples do not need special pretreatment, and the combined surface area is enlarged and the reaction is more thorough for ractopamine and salbutamol samples lower than the detection limit through the enrichment effect of the immunomagnetic beads and the full diffusion of the immunomagnetic beads in liquid, so that the detection limit can be changed, the detection sensitivity is improved, and the phenomenon of missed detection is avoided.
Detailed Description
In order to make those skilled in the art better understand the technical solution of the present invention, the present invention is further described in detail by the following examples, which are only used for illustrating the present invention and do not limit the scope of the present invention, and the following specific embodiments of the present invention are described below.
Example 1
Firstly, preparing immunomagnetic beads of anti-ractopamine monoclonal antibodies and anti-salbutamol monoclonal antibodies:
1. putting the magnetic beads into a centrifuge tube, adding an activation buffer solution to wash the magnetic beads, repeating the steps for three times at an interval of 3 minutes each time, removing the activation buffer solution, adding 200 mu L of activating agents EDC and NHS respectively, uniformly mixing, performing rotary incubation at 37 ℃ for 2 hours, and performing magnetic bead activation;
2. washing the magnetic beads for three times by using a coupling buffer solution, adding 0.5mg of anti-ractopamine monoclonal antibody and 1mg of anti-salbutamol monoclonal antibody, uniformly mixing, and incubating at 37 ℃ for 3 hours to prepare composite immunomagnetic beads containing the anti-ractopamine monoclonal antibody and the anti-salbutamol monoclonal antibody;
3. washing of the immunomagnetic beads with the washing buffer was repeated three times with 3 minute intervals. Incubating for 2 hours at 37 ℃ by using a confining liquid, and storing in a storage buffer solution at 4 ℃ for later use;
4. and loading the cleaned composite immunomagnetic beads into a matched test kit of the immunomagnetic bead solid phase carrier for subsequent use.
Secondly, the application of the composite immunomagnetic bead purification kit for ractopamine and salbutamol to the enrichment of ractopamine and salbutamol in feed samples:
1. weighing 5.0 g of feed sample, putting the feed sample into a test tube, adding a certain sample extracting solution, pretreating the sample, centrifuging and rotating, taking supernatant, and putting the supernatant into a sample tube position;
2. taking out immunomagnetic beads containing anti-ractopamine monoclonal antibodies and anti-salbutamol monoclonal antibodies, recovering to room temperature, and suspending with light shaking without sedimentation;
3. and (2) taking the supernatant obtained in the step (1), adding immunomagnetic beads containing anti-ractopamine monoclonal antibodies and anti-salbutamol monoclonal antibodies into the supernatant by using a magnetic rod, fully and uniformly mixing, incubating at 37 ℃ for 15 minutes, after the reaction is finished, placing the mixture on a magnetic frame to capture the magnetic beads, and slowly pouring out the supernatant. Washing with buffer solution for 3 times to obtain immunomagnetic beads for enriching ractopamine and salbutamol in the sample;
4. and (4) eluting the immunomagnetic beads of the enriched ractopamine and salbutamol in the step (3) by using an organic solvent, shaking for a few seconds at room temperature, carrying out magnetic separation, and obtaining supernate, namely the ractopamine and salbutamol to be detected in the sample, wherein the supernate can be used for HPLC (high performance liquid chromatography) or enzyme-linked immunosorbent assay.
Example 2
Firstly, preparing immunomagnetic beads of anti-ractopamine monoclonal antibodies and anti-salbutamol monoclonal antibodies:
1. putting the magnetic beads into a centrifuge tube, adding an activation buffer solution to wash the magnetic beads, repeating the steps for three times at an interval of 3 minutes each time, removing the activation buffer solution, adding 150 mu L of activating agents EDC and NHS respectively, uniformly mixing, performing rotary incubation at 37 ℃ for 2 hours, and performing magnetic bead activation;
2. washing the magnetic beads for three times by using a coupling buffer solution, adding 1mg of anti-ractopamine monoclonal antibody and 1.5mg of anti-salbutamol monoclonal antibody, uniformly mixing, and incubating at 37 ℃ for 3 hours to prepare composite immunomagnetic beads containing the anti-ractopamine monoclonal antibody and the anti-salbutamol monoclonal antibody;
3. and washing the composite immunomagnetic beads with washing buffer solution for three times repeatedly, wherein the time interval between each washing is 3 minutes. Incubating for 2 hours at 37 ℃ by using a confining liquid, and storing in a storage buffer solution at 4 ℃ for later use;
secondly, the application of the composite immunomagnetic bead purification kit for ractopamine and salbutamol to the enrichment of ractopamine and salbutamol in feed samples:
1. mashing the animal tissue sample with a meat mincing machine or mincing with a knife (slurry);
2. weighing 5.0 g of mashed tissue sample, putting the tissue sample into a 5 mL freezing tube, and screwing down a tube cover; and (3) boiling the freezing tube with the sample in boiling water for 10 minutes, taking out the freezing tube and cooling the freezing tube to room temperature for later use. Preparing sample homogenizing liquid, and placing the sample homogenizing liquid into a sample tube position;
3. and taking out the immunomagnetic beads containing the anti-ractopamine monoclonal antibody and the anti-salbutamol monoclonal antibody, recovering to room temperature, and suspending by gentle shaking without sedimentation. And (3) taking the sample homogenizing solution in the step (2), adding immunomagnetic beads containing anti-ractopamine monoclonal antibodies and anti-salbutamol monoclonal antibodies into the sample homogenizing solution by using a magnetic rod, fully and uniformly mixing, incubating at 37 ℃ for 15 minutes, after the reaction is finished, placing on a magnetic frame to capture the magnetic beads, and slowly pouring out the supernatant. And washing the sample for 3 times by using a buffer solution to obtain the immunomagnetic beads for enriching the ractopamine and the salbutamol in the sample.
4. And (4) eluting the immunomagnetic beads of the enriched ractopamine and salbutamol in the step (3) by using an organic solvent, shaking for a few seconds at room temperature, carrying out magnetic separation, and obtaining supernate, namely the ractopamine and salbutamol to be detected in the sample, wherein the supernate can be used for HPLC (high performance liquid chromatography) or enzyme-linked immunosorbent assay.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as no contradiction exists between the combinations of the technical features.
The above embodiments only show some embodiments of the present invention, and the description is specific and detailed, but it should not be understood that the scope of the patent is limited thereby, and it should be noted that, for those skilled in the art, many variations and modifications can be made without departing from the spirit of the invention, and these embodiments are all within the scope of the present invention.
Claims (6)
1. A composite immunomagnetic bead purification kit of ractopamine and salbutamol takes immunomagnetic beads as solid phase carriers, and is activated through chemical reaction, the activated immunomagnetic beads are coupled with ractopamine antibodies and salbutamol antibodies, and a matched test kit of the immunomagnetic bead solid phase carriers is loaded, so that a sample pretreatment kit capable of realizing rapid enrichment and purification of ractopamine antibodies and salbutamol antibodies is prepared.
2. The kit for purifying ractopamine and salbutamol composite immunomagnetic beads according to claim 1, wherein the concentration of the immunomagnetic beads is 5-100 mg/mL.
3. The kit for purifying ractopamine and salbutamol composite immunomagnetic beads according to claim 1, wherein each immunomagnetic bead purification kit contains 0.5-5mg/mL of anti-ractopamine monoclonal antibody and 0.5-8mg/mL of anti-salbutamol monoclonal antibody.
4. The kit for purifying the composite immunomagnetic beads of ractopamine and salbutamol according to claim 1, which is characterized by comprising the following steps:
taking the immunomagnetic beads coupled with the ractopamine antibody and the salbutamol antibody out of the refrigerator, recovering to room temperature, slowly rotating and uniformly mixing, putting the pretreated sample solution into a test tube, transferring the immunomagnetic beads into the test tube through a magnetic rod, fully rotating and resuspending, and rotating and capturing for 15min at room temperature to capture the ractopamine and the salbutamol in the sample to the maximum extent, performing magnetic separation by using a magnetic frame, and slowly discarding the supernatant; washing the captured immunomagnetic beads of the sample by using a cleaning solution for several times, and gently shaking for resuspension and magnetic separation; enrichment and purification of samples of ractopamine and salbutamol have been achieved.
5. The kit for purifying the composite immunomagnetic beads of ractopamine and salbutamol according to claim 1, wherein the immunomagnetic beads of ractopamine and salbutamol are eluted by an organic solvent, and are shaken for a few seconds at room temperature, and then subjected to magnetic separation, and the supernatant is the ractopamine and salbutamol to be detected, and can be used for HPLC (high performance liquid chromatography) or ELISA (enzyme-linked immunosorbent assay) determination.
6. The kit for purifying ractopamine and salbutamol composite immunomagnetic beads according to claim 1, wherein the immunomagnetic bead preservation solution is PBS buffer solution with pH7.4 and 0.02mo 1/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010030570.0A CN111024952A (en) | 2020-01-13 | 2020-01-13 | Composite immunomagnetic bead purification kit for ractopamine and salbutamol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010030570.0A CN111024952A (en) | 2020-01-13 | 2020-01-13 | Composite immunomagnetic bead purification kit for ractopamine and salbutamol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111024952A true CN111024952A (en) | 2020-04-17 |
Family
ID=70198866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010030570.0A Pending CN111024952A (en) | 2020-01-13 | 2020-01-13 | Composite immunomagnetic bead purification kit for ractopamine and salbutamol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111024952A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114184780A (en) * | 2021-12-03 | 2022-03-15 | 中国农业大学 | Method for detecting ractopamine by immunomagnetic bead purification-enzyme linked immunosorbent assay and single-chain antibody thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274334B1 (en) * | 2000-07-13 | 2001-08-14 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibody, cell line and immunoassay for ractopamine |
| US20050037386A1 (en) * | 2003-05-05 | 2005-02-17 | Drug Risk Solutions, L.L.C. | Composition and processes for analysis of pharmacologic agents in biological samples |
| CN103076416A (en) * | 2011-11-15 | 2013-05-01 | 南昌大学 | Method for enriching clenbuterol, ractopamine and salbutamol in urine sample of breeding livestock |
| CN105277424A (en) * | 2015-09-21 | 2016-01-27 | 北京勤邦生物技术有限公司 | Ractopamine immunomagnetic bead separation enrichment kit and application |
| CN106932584A (en) * | 2015-12-31 | 2017-07-07 | 北京勤邦生物技术有限公司 | A kind of salbutamol immuno magnetic cell separation enrichment kit and its application |
-
2020
- 2020-01-13 CN CN202010030570.0A patent/CN111024952A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274334B1 (en) * | 2000-07-13 | 2001-08-14 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibody, cell line and immunoassay for ractopamine |
| US20050037386A1 (en) * | 2003-05-05 | 2005-02-17 | Drug Risk Solutions, L.L.C. | Composition and processes for analysis of pharmacologic agents in biological samples |
| CN103076416A (en) * | 2011-11-15 | 2013-05-01 | 南昌大学 | Method for enriching clenbuterol, ractopamine and salbutamol in urine sample of breeding livestock |
| CN105277424A (en) * | 2015-09-21 | 2016-01-27 | 北京勤邦生物技术有限公司 | Ractopamine immunomagnetic bead separation enrichment kit and application |
| CN106932584A (en) * | 2015-12-31 | 2017-07-07 | 北京勤邦生物技术有限公司 | A kind of salbutamol immuno magnetic cell separation enrichment kit and its application |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114184780A (en) * | 2021-12-03 | 2022-03-15 | 中国农业大学 | Method for detecting ractopamine by immunomagnetic bead purification-enzyme linked immunosorbent assay and single-chain antibody thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108508199A (en) | A kind of salbutamol Sample pretreatment kit based on immunomagnetic beads | |
| CN100501409C (en) | ELISA kit for detecting chloramphenicols in animal derived food | |
| CN108828208A (en) | A kind of aflatoxin pretreatment reagent kit using immunomagnetic bead technique | |
| CN105301234B (en) | Clenbuterol immunomagnetic bead separation and enrichment kit and application thereof | |
| CN108982842A (en) | A kind of zearalenone pretreatment reagent kit using immunomagnetic bead technique | |
| CN110736835B (en) | Kit for measuring immunosuppressant cyclosporine A in whole blood by high-sensitivity latex-enhanced turbidimetric immunoassay | |
| CN108896676A (en) | A kind of magnetic Nano microsphere and its method to five kinds of trace fluoroquinolone antibiotics extractions and analysis in water body | |
| CN1766630A (en) | ELISA kit for detecting ractopamine in animal derived food | |
| CN105572370A (en) | Time-resolved fluorescent immunoassay kit for detecting neomycin and detecting method of kit | |
| CN109023535A (en) | A kind of DNA encoding method for screening compound being directed to antibody without identification labelled protein or cell lysate | |
| CN111024952A (en) | Composite immunomagnetic bead purification kit for ractopamine and salbutamol | |
| CN105277424A (en) | Ractopamine immunomagnetic bead separation enrichment kit and application | |
| CN110007078A (en) | A kind of Sample pretreatment kit of deoxynivalenol enol | |
| CN111024953A (en) | Composite immunomagnetic bead purification kit for ractopamine and terenclo hydrochloride | |
| JPH0641172A (en) | Method for separating ca195-like substance from human amniotic fluid | |
| CN111024951A (en) | Compound immunomagnetic bead purification kit of terencloro hydrochloride and salbutamol | |
| CN104031886A (en) | Method of detecting monensin by immunomagnetic bead purification-enzyme-linked immunoassay and special monoclonal antibody used therein | |
| CN110007079A (en) | A kind of Sample pretreatment extracts kit of ochratoxin A | |
| CN108866060B (en) | Nucleic acid aptamer specifically binding to crustacean arginine kinase, kit and detection method | |
| CN100406116C (en) | Method of purifying albuterol and/or clenbuterol and immune affinity chromatographic column | |
| CN114740122B (en) | Method for detecting lincomycin in animal food | |
| CN103969431B (en) | A kind of preparation method of the immunomagnetic beads for hidden state T-2 toxin enrichment purification | |
| CN108627643A (en) | A kind of Ractopamine Sample pretreatment kit based on immunomagnetic beads | |
| CN109283347A (en) | The method that nano biological sensor based on immunomagnetic beads and fluorescence quantum quickly detects Enrofloxacin in broiler chicken | |
| CN108982841A (en) | A kind of sulfamido Sample pretreatment kit based on immunomagnetic beads |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200417 |